Navigation Links
Boehringer Ingelheim's Investigational Therapy Nintedanib Receives FDA Breakthrough Therapy Designation
Date:7/16/2014

>Nintedanib was granted Priority Review designation in June 2014, Fast Track designation in June 2013 and orphan drug status in June 2011.

About nintedanib
Nintedanib is an investigational small molecule tyrosine kinase inhibitor (TKI) in development by Boehringer Ingelheim for idiopathic pulmonary fibrosis (IPF). It targets growth factors, which have been shown to be potentially involved in pulmonary fibrosis – the vascular endothelial growth factor receptor (VEGFR), fibroblast growth factor receptor (FGFR), and platelet-derived growth factor receptor (PDGFR).

About idiopathic pulmonary fibrosis
Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive, severely debilitating and ultimately fatal lung disease for which there are no FDA-approved treatment options in the U.S. Although lung transplantation has been shown to improve survival, the procedure is uncommon because of the limited availability of lungs for transplantation, or people are either too ill or don't survive long enough to undergo the transplant. The incidence of IPF can vary considerably, and there is some evidence that the population is increasing. IPF is characterized by progressive scarring of lung tissue and loss of lung function over time. Development of scarred tissue is called fibrosis. Over time, as the tissue thickens and stiffens with scarring, the lungs lose their ability to take in and transfer oxygen into the bloodstream, and vital organs do not get enough oxygen. As a result, individuals with IPF experience shortness of breath, cough and often have difficulty participating in everyday physical activities.

About Boehringer Ingelheim Pharmaceuticals, Inc.
Boehringer Ingelheim Pharmaceuticals, Inc., based in Ridgefield Conn., is the largest U.S. subsidiary of Boehringer Ingelheim Corporation (Ridgefield, CT) and a member of the Boehringer Ingelheim group of companies.

The Boehringer Inge
'/>"/>

SOURCE Boehringer Ingelheim Pharmaceuticals, Inc.
Copyright©2014 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Circuit Therapeutics and Boehringer Ingelheim announce signature of a research partnership agreement to discover new approaches to treating psychiatric disorders
2. Apollo Medical Holdings and Boehringer Ingelheim to Collaborate On Care of ApolloMed Accountable Care Organization (ACO) Patients with COPD
3. Largest Global Survey Investigating Early Type 2 Diabetes Conversations Launched by Boehringer Ingelheim and Eli Lilly and Company in Partnership with the International Diabetes Federation
4. Boehringer Ingelheims Jeff Huth Elected as National Pharmaceutical Councils Chairman of the Board
5. Boehringer Ingelheims interferon-free hepatitis C treatment portfolio strengthened by promising interim Phase 2a data
6. Pivotal Phase 3 Data from Boehringer Ingelheim Hepatitis C Portfolio to be Presented at 64th Annual AASLD Meeting
7. Boehringer Ingelheim Pharmaceuticals, Inc. colabora con Univision Communications Inc. para lanzar una campaña integrada en español
8. Boehringer Ingelheim Pharmaceuticals, Inc. Collaborates With Univision Communications Inc. To Launch An Integrated Campaign In Spanish
9. Boehringer Ingelheims investigational volasertib receives FDA Breakthrough Therapy designation
10. Boehringer Ingelheim Expands Investigation of Interferon-free Hepatitis C Treatment Regimens to Reach More Patient Types through Presidio Pharmaceuticals Clinical Collaboration
11. Boehringer Ingelheim Pharmaceuticals, Inc. Statement on RE-ALIGN Data
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2015)... , May 21, 2015 The ... statement regarding the Medicare Part D offsets included ... Cures initiative: "If the 21st Century Cures ... from America,s premier health program – Medicare – ... may yield down the road. "Leveraging ...
(Date:5/21/2015)... , May 21, 2015 /PRNewswire/ ... von Arzneimittelfälschungen - Zwecks Leistungsvergleich zur ... wird auf EG-Mitgliedstaaten verwiesen, in denen ... werden.  Wählen Sie ein Aegate-Land: beispielsweise ... Richtlinie zur Bekämpfung von Arzneimittelfälschungen (FMD) ...
(Date:5/21/2015)... , May 21, 2015 In praising ... Cures legislation by the House Energy and Commerce ... the Committee for recognizing the unique challenges facing ... for including bill language exempting Part D beneficiaries ... a proposed medication management "lock-in" provision. The SCPC ...
Breaking Medicine Technology:EU-Arzneimittel-Richtlinie für gefälschte Medikamente; Aegate-Zusammenfassung als reale Bewertung aus Belgien 2EU-Arzneimittel-Richtlinie für gefälschte Medikamente; Aegate-Zusammenfassung als reale Bewertung aus Belgien 3SCPC Applauds Unanimous House Panel Passage of 21st Century Cures Bill Recognizing Unique Challenges Facing Long Term Care (LTC) Pharmacy Patients, Providers 2
... July 14, 2011 Boston Scientific Corporation (NYSE: ... for the second quarter ended June 30, 2011 on Thursday, ... will be hosted by Ray Elliott, President and Chief Executive ... Officer. A live webcast of the discussion will ...
... MSA ), the global leader in the development, ... safety, announced today that it will broadcast a second quarter ... July 28, 2011 at 10:00 a.m. Eastern Time.  The call ... parties will have the opportunity to listen to the conference ...
Cached Medicine Technology:Boston Scientific to Webcast Conference Call Discussing Second Quarter 2011 Financial Results 2MSA Schedules Second Quarter Earnings Webcast 2
(Date:5/22/2015)... Mountain Point Medical Center, a campus of ... on Friday, May 29, 2015 at 11 a.m., followed by ... new medical center, set to officially open on June 1, ... 84043. , “The opening of Mountain Point Medical Center ... County community,” said Kent Loosle, CEO of Mountain Point Medical ...
(Date:5/22/2015)... 22, 2015 Omar Ahmad Barrada, a ... participate in the 2015 Congress of Future Medical Leaders ... a gathering of “America’s highest achieving high school students.” ... healthcare, set new goals and learn better study habits,” ... surgery, during which we can ask the surgeons questions.” ...
(Date:5/22/2015)... 22, 2015 Family, friends, students, colleagues, ... surgical oncologist, Dr. LaSalle D. Leffall, on Monday, May ... began after Grand Rounds in the hospital’s Tower Auditorium. ... outside the auditorium, trying to keep the secret. “I’d ... he sees me, he’ll know something is up,” she ...
(Date:5/22/2015)... 2015 According to a new Aegis Living ... equally as likely to worry about what will happen to ... 77% Boomers, 69% Silent Generation), which may help explain why ... of aging, particularly Millennials (47%), Gen X’ers (51%), and Boomers ... April, 2015 among more than 2,000 U.S. adults ages 18+. ...
(Date:5/22/2015)... According to Berks and Beyond , Pennsylvania ... totaling almost 2,500 confirmed drug deaths, as reported on May ... 2,489 deaths stemming from legal and illegal drug use in ... every day to fatal overdoses or other drug related deaths. ... of the most rife with drug related deaths. The city, ...
Breaking Medicine News(10 mins):Health News:Mountain Point Medical Center, a Campus of Jordan Valley Medical Center, Hosts Ribbon Cutting Ceremony and Community Celebration on Friday, May 29, 2015 2Health News:Milton Hershey School Student Chosen for Congress of Future Medical Leaders 2Health News:Colleagues Surprise Dr. LaSalle Leffall with 85th Birthday Celebration 2Health News:New Study Reveals America’s Fear of Aging 2Health News:New Study Reveals America’s Fear of Aging 3Health News:Philadelphia Ranks Among the Tops Cities in Penn. for Drug Deaths 2
... - Aspreva Pharmaceuticals,Corporation (NASDAQ: ASPV ; TSX: ... the Investment Canada Act, has approved the acquisition ... wholly-owned Canadian,subsidiary at a price of US$26.00 per ... being carried out by way of a statutory ...
... FRIDAY, Dec. 21 (HealthDay News) -- Screening tests for ... U.S. women cost about $150 annually per woman screened, ... cost per woman each year, including administrative, quality assurance, ... analysis of the National Breast and Cervical Cancer Early ...
... Medical,Technologies, Inc. (Nasdaq: PMTI ), a leading ... today announced an agreement,with The Gillette Company (a ... (NYSE: PG )) to extend the Launch ... women until no later than February 29,2008. Under ...
... indications than any other ... drug-eluting stent, ... announced today that its TAXUS(R) Liberte(TM),paclitaxel-eluting coronary stent system has received ... submitted,data showing the TAXUS Liberte stent has benefited diabetic patients with,coronary ...
... GLENDALE, Calif., Dec. 21 The California Nurses,Association/National ... failing to approve a liver transplant one week ... night just hours,after CIGNA relented and agreed to ... Dec. 11, four leading physicians, including the surgical ...
... Dec. 21 NPS,Pharmaceuticals, Inc. (Nasdaq: NPSP ) ... present a company update at the JPMorgan,26th Annual Healthcare ... on,Wednesday, January 9, 2008. The live event webcast may ... replay will be available approximately 24,hours after the presentation ...
Cached Medicine News:Health News:Aspreva receives Investment Canada approval for acquisition by Galenica 2Health News:Aspreva receives Investment Canada approval for acquisition by Galenica 3Health News:Aspreva receives Investment Canada approval for acquisition by Galenica 4Health News:Low-Income Women's Cancer Screenings Cost Effective: Report 2Health News:Low-Income Women's Cancer Screenings Cost Effective: Report 3Health News:Palomar and Gillette Extend Launch Decision on Home-Use Light Based Hair Removal Device and Agree to Negotiate New Terms 2Health News:Palomar and Gillette Extend Launch Decision on Home-Use Light Based Hair Removal Device and Agree to Negotiate New Terms 3Health News:Palomar and Gillette Extend Launch Decision on Home-Use Light Based Hair Removal Device and Agree to Negotiate New Terms 4Health News:TAXUS(R) Liberte(TM) Drug-eluting Coronary Stent System Receives CE Mark for Use in Diabetic Patients 2Health News:TAXUS(R) Liberte(TM) Drug-eluting Coronary Stent System Receives CE Mark for Use in Diabetic Patients 3Health News:TAXUS(R) Liberte(TM) Drug-eluting Coronary Stent System Receives CE Mark for Use in Diabetic Patients 4Health News:TAXUS(R) Liberte(TM) Drug-eluting Coronary Stent System Receives CE Mark for Use in Diabetic Patients 5Health News:RN's Statement on Death of Nataline Sarkisyan: 'CIGNA Should Have Listened to her Doctors and Approved the Transplant a Week Ago' 2
...
... a semi-rigid system intended for anterior ... is based on the comprehensive, clinically ... technology. The Slim-LOC system offers maximum ... width (16 mm), low profile (2.1 ...
... Osmium is a cervical plate system ... spine. The implant provides for the ... the bone transplant has consolidated. Optimized ... and bicortical fixation. Maximum purchase also ...
... is designed to meet the clinical challenges ... attached locking mechanism and the choice of ... variable angle screws for ease of implantation ... plate system allows the surgeon the versatility ...
Medicine Products: